keyword
MENU ▼
Read by QxMD icon Read
search

Abbvie

keyword
https://www.readbyqxmd.com/read/29748914/is-patient-support-program-participation-associated-with-longer-persistence-and-improved-adherence-among-new-users-of-adalimumab-a-retrospective-cohort-study
#1
Einav Srulovici, Vishvas Garg, Adi Ghilai, Becca Feldman, Moshe Hoshen, Ran D Balicer, Martha Skup, Maya Leventer-Roberts
INTRODUCTION: Adalimumab (ADA) is a medication used in the treatment of several autoimmune diseases. Despite the beneficial effects of ADA, its adherence and persistence rates are low. Patients treated with ADA from Clalit Health Services (CHS) can enroll in AbbVie's patient support program (PSP), which aims to improve ADA adherence and persistence. Therefore, we examine whether PSP participation is associated with a longer persistence and/or an improved adherence to ADA. METHODS: A real-world retrospective cohort study of all new ADA users from CHS, comparing those enrolled in the offered PSP to those not enrolled...
May 10, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29747158/delayed-return-to-estrus-following-treatment-with-the-gonadotrophin-releasing-hormone-agonist-lucrin-%C3%A2-depot-in-the-tammar-wallaby
#2
Ryan R Witt, Lyn A Hinds, John C Rodger
Gonadotrophin-releasing hormone agonists that induce a reversible contraceptive state in several marsupials have the potential to be used to synchronize estrus. We used a model macropod, the tammar wallaby (Notamacropus eugenii), to investigate whether Lucrin Depot (AbbVie), a GnRH agonist microsphere preparation, could (1) inhibit follicular development and estrus in a cycle reactivated by removal of pouch young (RPY) and (2) facilitate a synchronous return to estrus. Our results show that females reactivated with bromocriptine and RPY in early seasonal quiescence (July 2015) were inhibited by Lucrin Depot (0...
April 30, 2018: Theriogenology
https://www.readbyqxmd.com/read/29694284/publicly-funded-oral-chronic-hepatitis-b-treatment-patterns-in-ontario-over-16-years-an-ecologic-study
#3
Mina Tadrous, Mayur Brahmania, Diana Martins, Sandra Knowles, Harry L A Janssen, Muhammad M Mamdani, David N Juurlink, Tara Gomes
BACKGROUND: Reimbursement for the use of hepatitis B virus (HBV) treatments has not been previously reported for public payers. OBJECTIVE: To describe the number of users and total cost of HBV treatments over the last 16 years among residents of Ontario, Canada, who were covered by the public drug program. METHODS: We conducted a repeated cross-sectional study for HBV treatments reimbursed by the public drug program in Ontario from January 1, 2000, to December 31, 2015...
May 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29688337/stimulation-of-s1pr5-with-a-971432-a-selective-agonist-preserves-blood-brain-barrier-integrity-and-exerts-therapeutic-effect-in-an-animal-model-of-huntington-s-disease
#4
Alba Di Pardo, Salvatore Castaldo, Enrico Amico, Giuseppe Pepe, Federico Marracino, Luca Capocci, Alfredo Giovannelli, Michele Madonna, Jeroen van Bergeijk, Fabio Buttari, Elizabeth van der Kam, Vittorio Maglione
Huntington's disease (HD) is the most common neurodegenerative disorder for which no effective cure is yet available. Although several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only symptomatic treatment available. Over the past few years, we have demonstrated that sphingolipid-based approaches may open the door to new and more targeted treatments for the disease.In this study, we investigated the therapeutic potential of stimulating Sphingosine-1-phosphate (S1P) receptor 5 by the new selective agonist A-971432 (provided by AbbVie) in R6/2 mice, a widely-used HD animal model...
April 24, 2018: Human Molecular Genetics
https://www.readbyqxmd.com/read/29676732/donated-chemical-probes-for-open-science
#5
Susanne Müller, Suzanne Ackloo, Cheryl H Arrowsmith, Marcus Bauser, Jeremy L Baryza, Julian Blagg, Jark Böttcher, Chas Bountra, Peter J Brown, Mark E Bunnage, Adrian J Carter, David Damerell, Volker Dötsch, David H Drewry, Aled M Edwards, James Edwards, Jon M Elkins, Christian Fischer, Stephen V Frye, Andreas Gollner, Charles E Grimshaw, Adriaan IJzerman, Thomas Hanke, Ingo V Hartung, Steve Hitchcock, Trevor Howe, Terry V Hughes, Stefan Laufer, Volkhart Mj Li, Spiros Liras, Brian D Marsden, Hisanori Matsui, John Mathias, Ronan C O'Hagan, Dafydd R Owen, Vineet Pande, Daniel Rauh, Saul H Rosenberg, Bryan L Roth, Natalie S Schneider, Cora Scholten, Kumar Singh Saikatendu, Anton Simeonov, Masayuki Takizawa, Chris Tse, Paul R Thompson, Daniel K Treiber, Amélia Yi Viana, Carrow I Wells, Timothy M Willson, William J Zuercher, Stefan Knapp, Anke Mueller-Fahrnow
Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical probes and several of these have been made available to academia. However, probe-associated data and control compounds, such as inactive structurally related molecules and their associated data, are generally not accessible. The lack of data and guidance makes it difficult for researchers to decide which chemical tools to choose...
April 20, 2018: ELife
https://www.readbyqxmd.com/read/29580099/global-medicinal-chemistry-and-gpcr-conference-interview-with-stevan-djuric
#6
Stevan Djuric
Stevan Djuric speaks to Benjamin Walden, Commissioning Editor. Stevan Djuric is head of the global Medicinal Chemistry Leadership Team at AbbVie and is also Vice President of the Discovery Chemistry and Technology organization within their Discovery organization and chemistry outsourcing activities. He spoke at the Global-Medicinal-Chemistry and GPCR summit on the imperative to develop chemistry related technology that can reduce cycle time, cost of goods and improve probability of success. To this end, he discussed his efforts in the chemistry technology area with a focus on integrated synthesis-purification bioassay, and flow photochemistry and high temperature chemistry platforms...
March 27, 2018: Future Medicinal Chemistry
https://www.readbyqxmd.com/read/29578854/increasing-access-to-hepatitis-c-virus-medications-a-program-model-using-patient-navigators-and-specialty-pharmacy-to-obtain-prior-authorization-approval
#7
Trang M Vu, Wilma Toribio, Farah Riazi, Genesis Ciprian, Nathalia Gibbs, Martha Giardina, Jocelyn A Camacho, Korin Parrella, Joy Cambe, Catherine Amory, Rachel Chasan, Keith M Sigel, Jeffrey J Weiss
BACKGROUND: Obtaining prior authorization (PA) approval for the new direct-acting antiviral (DAA) hepatitis C medications is time consuming and requires specific expertise. Our primary care-based program treats hepatitis C virus (HCV)-infected patients at an urban academic medical center and employs patient navigators trained in the PA process who collaborate with a nurse and specialty pharmacy to manage the PA process. OBJECTIVE: To demonstrate the rate of PA approvals for our programmatic model and determine potential predictors of PA approval...
April 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29578852/economic-burden-of-patients-with-inadequate-response-to-targeted-immunomodulators-for-rheumatoid-arthritis
#8
Vibeke Strand, Namita Tundia, Yan Song, Dendy Macaulay, Mahesh Fuldeore
BACKGROUND: Targeted immunomodulators (TIMs), including biologic disease-modifying antirheumatic drugs (DMARDs) and JAK/STAT inhibitors, are effective therapies for rheumatoid arthritis (RA), but some patients fail to respond or lose response over time. This study estimated the real-world prevalence of RA patients with inadequate responses to an initial TIM (nonresponders) in the United States and assessed their direct and indirect economic burden compared with treatment responders. METHODS: Administrative claims data (January 1999-March 2014) from a large private-insurer database were used, which included work-loss data from a subset of reporting companies...
April 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29574622/similar-improvements-in-patient-reported-outcomes-among-rheumatoid-arthritis-patients-treated-with-two-different-doses-of-methotrexate-in-combination-with-adalimumab-results-from-the-musica-trial
#9
Gurjit S Kaeley, Daryl K MacCarter, Janak R Goyal, Shufang Liu, Kun Chen, Jennifer Griffith, Hartmut Kupper, Vishvas Garg, Jasmina Kalabic
INTRODUCTION: In patients with rheumatoid arthritis (RA), combination treatment with methotrexate (MTX) and adalimumab is more effective than MTX monotherapy. From the patients' perspective, the impact of reduced MTX doses upon initiating adalimumab is not known. The objective was to evaluate the effects of low and high MTX doses in combination with adalimumab initiation on patient-reported outcomes (PROs), in MTX-inadequate responders (MTX-IR) with moderate-to-severe RA. METHODS: MUSICA was a randomized, double-blind, controlled trial evaluating the efficacy of 7...
March 24, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29562156/venetoclax-rituximab-in-relapsed-or-refractory-chronic-lymphocytic-leukemia
#10
RANDOMIZED CONTROLLED TRIAL
John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, John Gerecitano, Tadeusz Robak, Javier De la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth A Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P Kater
BACKGROUND: Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. METHODS: In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax-rituximab group) or bendamustine plus rituximab for 6 months (bendamustine-rituximab group)...
March 22, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29530196/breeding-in-the-fat-tailed-dunnart-following-ovarian-suppression-with-the-gonadotrophin-releasing-hormone-agonist-lucrin-%C3%A2-depot
#11
Ryan R Witt, John J Rodger, John C Rodger
Lucrin Depot (AbbVie), a 1-month microsphere gonadotrophin-releasing hormone (GnRH) agonist preparation, was investigated as a potential agent to synchronise cycling in the fat-tailed dunnart (Sminthopsis crassicaudata). Forty-eight randomly selected females were treated with 5 or 10mgkg-1 Lucrin Depot (n=24 per dose). Eighteen females per treatment had their reproductive activity scored at 4, 8, 12 and 16 weeks using two ovarian (Graafian follicle and corpus luteum status) and two reproductive tract (uterine and vaginal muscularity and vascularity) parameters that formed a reproductive activity score...
March 2018: Reproduction, Fertility, and Development
https://www.readbyqxmd.com/read/29519714/impact-of-the-adalimumab-patient-support-program-s-care-coach-calls-on-persistence-and-adherence-in-canada-an-observational-retrospective-cohort-study
#12
John K Marshall, Louis Bessette, Carter Thorne, Neil H Shear, Gerald Lebovic, Sebastien K Gerega, Brad Millson, Driss Oraichi, Tania Gaetano, Sandra Gazel, Martin G Latour, Marie-Claude Laliberté
PURPOSE: Adalimumab (ADA) is a tumor necrosis factor-α inhibitor indicated for use in various immune-mediated inflammatory diseases. Patients receiving ADA in Canada are eligible to enroll in the AbbVie Care's Patient Support Program (PSP), which provides personalized services, including tailored interventions in the form of nurse-provided care coach calls (CCCs), with the goal of improving patients' experiences and outcomes. The primary objective of this study was to evaluate the impact of PSP services, including CCCs and patient characteristics, on persistence with and adherence to ADA for those patients enrolled in the PSP...
March 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29516410/adalimumab-reduces-extraintestinal-manifestations-in-patients-with-crohn-s-disease-a-pooled-analysis-of-11-clinical-studies
#13
Edouard J Louis, Walter Reinisch, David A Schwartz, Robert Löfberg, Anne M Robinson, Sofie Berg, Anthony W Wang, Jen-Fue Maa, Bidan Huang, Brandee Pappalardo
INTRODUCTION: Extraintestinal manifestations (EIMs) in patients with Crohn's disease (CD) are common and associated with additional morbidity. This study aimed to evaluate the effect of adalimumab therapy on EIM resolution and identify potential predictors of EIM resolution in adult and pediatric patients with moderate to severe CD. METHODS: EIM data were pooled from 11 induction, maintenance, and open-label extension studies of adalimumab. Resolution of EIMs was evaluated at approximately 6 months and 1 year...
April 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29501363/addition-of-the-parp-inhibitor-veliparib-plus-carboplatin-or-carboplatin-alone-to-standard-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-brightness-a-randomised-phase-3-trial
#14
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag, Danielle Sullivan, Norman Wolmark, Kristi McIntyre, Jose J Ponce Lorenzo, Otto Metzger Filho, Priya Rastogi, W Fraser Symmans, Xuan Liu, Charles E Geyer
BACKGROUND: Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelihood of achieving a pathological complete response, the use of these therapies in this setting has remained controversial. The BrighTNess trial was designed to assess the addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer...
April 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29500030/respiratory-syncytial-virus-prevention-and-asthma-in-healthy-preterm-infants-a-randomised-controlled-trial
#15
Nienke M Scheltema, Elisabeth E Nibbelke, Juliëtte Pouw, Maarten O Blanken, Maroeska M Rovers, Christiana A Naaktgeboren, Natalie I Mazur, Joanne G Wildenbeest, Cornelis K van der Ent, Louis J Bont
BACKGROUND: Respiratory syncytial virus (RSV) infection is associated with subsequent wheeze and asthma. We previously reported on the causal relationship between prevention of RSV infection during infancy and reduced frequency of subsequent wheeze using a double-blind, randomised, placebo-controlled trial (MAKI). We continued follow-up and analysed the effect of RSV prevention during infancy on asthma and lung function at age 6 years. METHODS: We studied 429 infants born at 32-35 weeks of gestation between 2008-10 who had randomly received either palivizumab for RSV immunoprophylaxis or placebo during the RSV season of their first year of life...
April 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29485951/predicting-acute-exacerbations-in-chronic-obstructive-pulmonary-disease
#16
Jennifer C Samp, Min J Joo, Glen T Schumock, Gregory S Calip, A Simon Pickard, Todd A Lee
BACKGROUND: With increasing health care costs that have outpaced those of other industries, payers of health care are moving from a fee-for-service payment model to one in which reimbursement is tied to outcomes. Chronic obstructive pulmonary disease (COPD) is a disease where this payment model has been implemented by some payers, and COPD exacerbations are a quality metric that is used. Under an outcomes-based payment model, it is important for health systems to be able to identify patients at risk for poor outcomes so that they can target interventions to improve outcomes...
March 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29470837/past-present-and-future-approaches-to-the-prevention-and-treatment-of-respiratory-syncytial-virus-infection-in-children
#17
REVIEW
Eric A F Simões, Louis Bont, Paolo Manzoni, Brigitte Fauroux, Bosco Paes, Josep Figueras-Aloy, Paul A Checchia, Xavier Carbonell-Estrany
INTRODUCTION: The REGAL (RSV Evidence - A Geographical Archive of the Literature) series has provided a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This seventh and final publication covers the past, present and future approaches to the prevention and treatment of RSV infection among infants and children. METHODS: A systematic review was undertaken of publications between January 1, 1995 and December 31, 2017 across PubMed, Embase and The Cochrane Library...
March 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29450864/real-world-evaluation-of-direct-and-indirect-economic-burden-among-endometriosis-patients-in-the-united-states
#18
Ahmed M Soliman, Eric Surrey, Machaon Bonafede, James K Nelson, Jane Castelli-Haley
INTRODUCTION: The prevalence of endometriosis and the need for treatment in the USA has led to the need to explore the contemporary cost burden associated with the disease. This retrospective cohort study compared direct and indirect healthcare costs in patients with endometriosis to a control group without endometriosis. METHODS: Women aged 18-49 years with endometriosis (date of initial diagnosis = index date) were identified in the Truven Health MarketScan® Commercial database between 2010 and 2014 and female control patients without endometriosis were matched by age and index year...
March 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29433614/hope-or-hype-in-the-treatment-of-schizophrenia-what-s-the-role-of-the-physician
#19
Rodrigo A Bressan, Geder E M Grohs, Gabriela Matos, Sukhi Shergill
According to the experience of people with schizophrenia, their psychiatrists' attitude towards the outcome of their illness is lacking in hope, which directly affects mutual faith in treatment. Here we discuss the scientific basis of hope and show its instrumental role in optimising the best treatment strategies for schizophrenia. Declaration of interest R.A.B has received honoraria for educational input and non-financial support from Ache; honoraria for educational input from Lundbeck; grants, honoraria for educational input and non-financial support from Janssen; all outside the submitted work...
January 2018: British Journal of Psychiatry: the Journal of Mental Science
https://www.readbyqxmd.com/read/29379635/reducing-the-osteoporosis-treatment-gap-an-interview-with-ucb-s-pascale-richetta
#20
Pascale Richetta
Dr. Pascale Richetta is Executive Vice President and Head of the Bone Patient Value Unit at UCB (Brussels, Belgium). She joined UCB in 2016 following over 20 years' experience in the pharma and biotech industry. After completing her MD at the University of Poitiers (France), she spent time as vice president at Abbvie/Abbott and has also held positions at GlaxoSmithKline, Ipsen and Servier. Through the course of her career she acquired impressive commercial experience managing both traditional pharmaceuticals and complex biologics and her knowledge of markets around the world is key to helping UCB prepare for future product launches...
February 2018: Future Science OA
keyword
keyword
23553
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"